Physician profile

Steven Lomasky

Endocrinology, Diabetes & Metabolism · Rockville Centre, NY

NPI 1891738456

$2,408.21

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $783.10 2019-2022
Sanofi-Aventis U.S. LLC $248.24 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $212.27 2019
Amgen INC. $200.76 2019-2020
Astrazeneca Pharmaceuticals LP $190.55 2019-2020
Insulet Corporation $94.30 2019
Lilly USA, LLC $82.45 2019-2020
Merck Sharp & Dohme LLC $76.49 2019
Dexcom, INC. $71.04 2019-2022
Amarin Pharma, INC. $67.35 2019
Tandem Diabetes Care, INC. $63.77 2019-2020
Ipsen Biopharmaceuticals, INC $49.31 2019
Abbvie INC. $46.46 2019
Abbott Laboratories $42.05 2019
Shire North American Group INC $39.57 2019
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Ibsa Pharma INC. $37.80 2019
Companion Medical, INC. $27.43 2019
Janssen Pharmaceuticals, INC $26.07 2019
Medtronic Minimed, INC. $19.57 2019
Horizon Therapeutics Plc $18.20 2019
Lifescan, INC. $11.43 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Steven Lomasky

$2,408.21

in general payments reported 2019-2025

Years
2019-2022
Top company
Novo Nordisk INC

https://glasscript.com/doctor/267666/steven-lomasky

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.